Correlation Between Qingdao NovelBeam and Hengkang Medical

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Qingdao NovelBeam and Hengkang Medical at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Qingdao NovelBeam and Hengkang Medical into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Qingdao NovelBeam Technology and Hengkang Medical Group, you can compare the effects of market volatilities on Qingdao NovelBeam and Hengkang Medical and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Qingdao NovelBeam with a short position of Hengkang Medical. Check out your portfolio center. Please also check ongoing floating volatility patterns of Qingdao NovelBeam and Hengkang Medical.

Diversification Opportunities for Qingdao NovelBeam and Hengkang Medical

0.93
  Correlation Coefficient

Almost no diversification

The 3 months correlation between Qingdao and Hengkang is 0.93. Overlapping area represents the amount of risk that can be diversified away by holding Qingdao NovelBeam Technology and Hengkang Medical Group in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Hengkang Medical and Qingdao NovelBeam is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Qingdao NovelBeam Technology are associated (or correlated) with Hengkang Medical. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Hengkang Medical has no effect on the direction of Qingdao NovelBeam i.e., Qingdao NovelBeam and Hengkang Medical go up and down completely randomly.

Pair Corralation between Qingdao NovelBeam and Hengkang Medical

Assuming the 90 days trading horizon Qingdao NovelBeam Technology is expected to under-perform the Hengkang Medical. But the stock apears to be less risky and, when comparing its historical volatility, Qingdao NovelBeam Technology is 1.64 times less risky than Hengkang Medical. The stock trades about -0.07 of its potential returns per unit of risk. The Hengkang Medical Group is currently generating about 0.07 of returns per unit of risk over similar time horizon. If you would invest  257.00  in Hengkang Medical Group on September 1, 2024 and sell it today you would earn a total of  13.00  from holding Hengkang Medical Group or generate 5.06% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthVery Strong
Accuracy95.65%
ValuesDaily Returns

Qingdao NovelBeam Technology  vs.  Hengkang Medical Group

 Performance 
       Timeline  
Qingdao NovelBeam 

Risk-Adjusted Performance

11 of 100

 
Weak
 
Strong
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Qingdao NovelBeam Technology are ranked lower than 11 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak basic indicators, Qingdao NovelBeam sustained solid returns over the last few months and may actually be approaching a breakup point.
Hengkang Medical 

Risk-Adjusted Performance

16 of 100

 
Weak
 
Strong
Solid
Compared to the overall equity markets, risk-adjusted returns on investments in Hengkang Medical Group are ranked lower than 16 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak basic indicators, Hengkang Medical sustained solid returns over the last few months and may actually be approaching a breakup point.

Qingdao NovelBeam and Hengkang Medical Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Qingdao NovelBeam and Hengkang Medical

The main advantage of trading using opposite Qingdao NovelBeam and Hengkang Medical positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Qingdao NovelBeam position performs unexpectedly, Hengkang Medical can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Hengkang Medical will offset losses from the drop in Hengkang Medical's long position.
The idea behind Qingdao NovelBeam Technology and Hengkang Medical Group pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.

Other Complementary Tools

Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance